 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Relmada Therapeutics Announces Efficacy and Safety Results from the Phase 3 Long-Term Study of REL-1017 in Major Depressive Disorder Relmada Therapeutics Announces Efficacy and Safety Results from...

Relmada Therapeutics Announces Efficacy and Safety Results from the Phase 3 Long-Term Study of REL-1017 in Major Depressive Disorder

This is a Bearish indicator signaling RLMD's price could decline from here. Traders may explore shorting the stock or put options...

Relmada Therapeutics (RLMD, $3.39) Moving Average Convergence Divergence (MACD) Histogram turned negative on September 12, 2023

This is a signal that RLMD's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

Relmada Therapeutics (RLMD, $3.67) RSI Indicator left the overbought zone on September 06, 2023

This is a signal that RLMD's price trend could be reversing, and it may be an opportunity to sell the stock or take a defensive position...

Relmada Therapeutics (RLMD, $3.79) Stochastic Oscillator left the overbought zone on September 01, 2023

Relmada Therapeutics: Run Up Likely Into Phase 3 Results, Enhanced By Possible Interim Readout...

Relmada Therapeutics: Run Up Likely Into Phase 3 Results, Enhanced By Possible Interim Readout

This indicator may be signaling RLMD's price has momentum to move higher, since its current price moved above its price 14 days ago. Traders may consider buying the stock or exploring call options...

Relmada Therapeutics (RLMD, $3.38) entered Uptrend as Momentum indicator ascends above 0 level on Aug 30, 2023

Relmada Therapeutics Announces Dosing of First Patient in Relight, a Phase 3 Trial of REL-1017 for the Adjunctive Treatment of Major Depressive Disorder Relmada Therapeutics Announces Dosing of First...

Relmada Therapeutics Announces Dosing of First Patient in Relight, a Phase 3 Trial of REL-1017 for the Adjunctive Treatment of Major Depressive Disorder

Mizuho Securities analyst Uy Ear maintained a Buy rating on Relmada Therapeutics (RLMD Research Report) today and set a price target of $25.00. T... Mizuho Securities analyst Uy Ear maintained a Buy rating on Relmada Therapeutics (RLMD  Research Report...

Mizuho Securities Reaffirms Their Buy Rating on Relmada Therapeutics (RLMD)

Shares of Relmada Therapeutics, Inc. (NASDAQ:RLMD  Get Free Report) have been assigned an average recommendation of Hold from the six research firms that are covering the firm...

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Given Average Rating of "Hold" by Brokerages

Relmada Therapeutics, Inc. (NASDAQ:RLMD  Get Free Report) has received an average rating of Hold from the six ratings firms that are covering the firm, MarketBeat.com reports...

Brokerages Set Relmada Therapeutics, Inc. (NASDAQ:RLMD) Target Price at $20.50

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on addressing diseases of the central nervous system. It develops esmethadone, an N-methyl-D-aspartate receptor antagonist for the treatment of CNS diseases, and oral agent for depression and other potential indications. The company was founded by Paolo Manfredi on May 31, 2012 and is headquartered in Coral Gables, FL.

Watchers	1,313
52-Wk Low	$1.81
52-Wk High	$38.68

Market Cap	$94.81M
Volume (M)	57.00
52-Wk High	$38.68
52-Wk Low	$1.81

RLMD Relmada Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals